| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2006. Published by Oxford University Press.
ARTICLE |
Supplemental and Dietary Vitamin E, 
-Carotene, and Vitamin C Intakes and Prostate Cancer Risk
On behalf of the PLCO Trial
Affiliations of authors: Division of Cancer Epidemiology and Genetics (VAK, RBH, NC, DA, UP), Division of Cancer Control and Population Sciences (AFS), National Cancer Institute, NIH, DHHS, Bethesda, MD; Division of Preventive Oncology, Cancer Care Ontario, Toronto, ON, Canada (VAK); Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT (STM, VAK); Department of Nutrition, Food Studies, and Public Health, New York University, New York, NY (LBD); Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO (GLA); Department of Surgery, Division of Urology, University of Alabama at Birmingham, Birmingham, AL (DAU); Fred Hutchinson Cancer Research Center, Seattle, WA (UP)
Correspondence to: Richard B. Hayes, PhD, EPN 8114, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd., Bethesda, MD 20892 (e-mail: hayesr{at}mail.nih.gov).
Background: Vitamin E, 
-carotene, and vitamin C are micronutrient antioxidants that protect cells from oxidative damage involved in prostate carcinogenesis. In separate trials, supplemental vitamin E was associated with a decreased risk of prostate cancer among smokers and supplemental -carotene was associated with a decreased risk of prostate cancer among men with low baseline plasma -carotene levels. Methods: We evaluated the association between intake of these micronutrient antioxidants from foods and supplements and the risk of prostate cancer among men in the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. At baseline, trial participants completed a 137-item food frequency questionnaire that included detailed questions on 12 individual supplements. Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. Results: We identified 1338 cases of prostate cancer among 29 361 men during up to 8 years of follow-up. Overall, there was no association between prostate cancer risk and dietary or supplemental intake of vitamin E, -carotene, or vitamin C. However, among current and recent (i.e., within the previous 10 years) smokers, decreasing risks of advanced prostate cancer (i.e., Gleason score 
7 or stage III or IV) were associated with increasing dose (RR for >400 IU/day versus none = 0.29, 95% CI = 0.12 to 0.68; Ptrend = .01) and duration (RR for 10 years of use versus none = 0.30, 95% CI = 0.09 to 0.96; Ptrend = .01) of supplemental vitamin E use. Supplemental -carotene intake at a dose level of at least 2000 µg/day was associated with decreased prostate cancer risk in men with low (below the median of 4129 µg/day) dietary -carotene intake (RR = 0.52, 95% CI = 0.33 to 0.81). Among smokers, the age-adjusted rate of advanced prostate cancer was 492 per 100 000 person-years in those who did not take supplemental vitamin E, 153 per 100 000 person-years in those who took more than 400 IU/day of supplemental vitamin E, and 157 per 100 000 person-years in those who took supplemental vitamin E for 10 or more years. Among men with low dietary -carotene intake, the age-adjusted rate of prostate cancer was 1122 per 100 000 person-years in those who did not take supplemental -carotene, and 623 per 100 000 person-years in those who took at least 2000 µg/day of supplemental -carotene. Conclusions: Our results do not provide strong support for population-wide implementation of high-dose antioxidant supplementation for the prevention of prostate cancer. However, vitamin E supplementation in male smokers and -carotene supplementation in men with low dietary -carotene intakes were associated with reduced risk of this disease.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- Vitamin E in the Prevention of Prostate Cancer: Where Are We Today?
- I-Min Lee, J. Michael Gaziano, and Julie E. Buring
J Natl Cancer Inst 2006 98: 225-227.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  J. Jayachandran and S. J. Freedland Prevention of Prostate Cancer: What We Know and Where We Are Going American Journal of Men's Health, June 1, 2008; 2(2): 178 - 189. [Abstract] [PDF]
|
|
|
|
 |
|
 T. J Key, P. N Appleby, N. E Allen, R. C Travis, A. W Roddam, M. Jenab, L. Egevad, A. Tjonneland, N. F Johnsen, K. Overvad, et al. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study Am. J. Clinical Nutrition, September 1, 2007; 86(3): 672 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kang, K.-M. Lee, S. K. Park, S. I. Berndt, U. Peters, D. Reding, N. Chatterjee, R. Welch, S. Chanock, W.-Y. Huang, et al. Functional Variant of Manganese Superoxide Dismutase (SOD2 V16A) Polymorphism Is Associated with Prostate Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Study Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1581 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Wright, S. J. Weinstein, K. A. Lawson, D. Albanes, A. F. Subar, L. B. Dixon, T. Mouw, A. Schatzkin, and M. F. Leitzmann Supplemental and Dietary Vitamin E Intakes and Risk of Prostate Cancer in a Large Prospective Study Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1128 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Weinstein, M. E. Wright, K. A. Lawson, K. Snyder, S. Mannisto, P. R. Taylor, J. Virtamo, and D. Albanes Serum and Dietary Vitamin E in Relation to Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1253 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Peters, C. B Foster, N. Chatterjee, A. Schatzkin, D. Reding, G. L Andriole, E D. Crawford, S. Sturup, S. J Chanock, and R. B Hayes Serum selenium and risk of prostate cancer--a nested case-control study Am. J. Clinical Nutrition, January 1, 2007; 85(1): 209 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Greenwald, D. Anderson, S. A Nelson, and P. R Taylor Clinical trials of vitamin and mineral supplements for cancer prevention Am. J. Clinical Nutrition, January 1, 2007; 85(1): 314S - 317S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Mayne and B. Cartmel Chemoprevention of Second Cancers Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2033 - 2037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dietrich, M. G Traber, P. F Jacques, C. E Cross, Y. Hu, and G. Block Does {gamma}-Tocopherol Play a Role in the Primary Prevention of Heart Disease and Cancer? A Review. J. Am. Coll. Nutr., August 1, 2006; 25(4): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I-M. Lee, J. M. Gaziano, and J. E. Buring Vitamin E in the prevention of prostate cancer: where are we today? J Natl Cancer Inst, February 15, 2006; 98(4): 225 - 227. [Full Text] [PDF]
|
|